SU-F-BRB-04: Comparison of Coplanar VMAT, Non-Coplanar VMAT, and 4π Treatment Plans

Authors


Abstract

Purpose:

The 4π non-coplanar radiotherapy delivery technique has demonstrated significantly better normal tissue sparing and dose conformality than the clinically used volumetric modulated arc therapy (VMAT). It is unclear whether this is a fundamental limitation of VMAT delivery or the coplanar nature of its typical clinical plans. The non-coplanar basis of 4π is incorporated into VMAT treatment planning to compare its effect on plan quality.

Methods:

Clinical stereotactic body radiation therapy plans for 9 liver patients treated with 30–60 Gy using coplanar VMAT (cVMAT) were re-planned using non-coplanar VMAT (nVMAT) with 3 arcs and 4 π with 20 intensity-modulated non-coplanar fields. All plans were optimized to deliver 100% of the prescribed dose to 95% of the planning target volume (PTV), and nVMAT and 4π plans were tailored to match the maximum and mean PTV dose from the clinical plan. The conformality index (CI), 50% dose spillage volume (R50), normal liver volume receiving >15 Gy (VL>15), and doses to organs at risk (OARs) were compared for all three treatment plans.

Results:

Compared to cVMAT, the nVMAT and 4π plans reduced VL>15 by an average of 30.6 cm3 and 96.3 cm3, respectively. The average CI was also reduced from 1.22 (cVMAT) to 1.17 (nVMAT) and 1.14 (4π), indicating higher conformality in the same order. Similarly, R50 was reduced from 3.87 (cVMAT) to 3.58 (nVMAT) and 2.74 (4π). With the exception of the mean right kidney dose, which increased by an average of only 0.6 Gy for nVMAT, the dose differences to OARs were not statistically significant between the two VMAT plans. 4π plans either significantly decreased or maintained OAR doses.

Conclusion:

While the manual selection of intuitive non-coplanar arcs does show some improvement over coplanar VMAT, the automated beam selection for 4π still results in superior plan quality.

This project is supported in part by Varian Medical Systems and NIH R43 CA183390.

Ancillary